Table 6. Conclusions on drugs to treat dementia in PD.

	Efficacy	Safety	Practice implications
Acetylcholinesterase inhibitors
Donepezil	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational
Rivastigmine	Efficacious	Acceptable risk without specialized monitoring	Clinically useful
Galantamine	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational
NMDA Receptor Antagonists
Memantine	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational

Treatments with new conclusions have gray backgrounds and italicized text, and those with no changes have white backgrounds.

PD, Parkinson's disease.